Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer.

Mod Pathol 2012 Nov 8;25(11):1473-80. Epub 2012 Jun 8.

Centre of Integrated Oncology Köln-Bonn, Institute of Pathology, University Hospital Cologne, Cologne, Germany.

We recently reported fibroblast growth factor receptor-type 1 (FGFR1) amplification to be associated with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. This makes FGFR1 a novel target for directed therapy in these tumors. To reproducibly identify patients for clinical studies, we developed a standardized reading and evaluation strategy for FGFR1 fluorescence in-situ hybridization (FISH) and propose evaluation criteria, describe different patterns of low- and high-level amplifications and report on the prevalence of FGFR1 amplifications in pulmonary carcinomas. A total of 420 lung cancer patients including 307 squamous carcinomas, 100 adenocarcinomas of the lung and 13 carcinomas of other types were analyzed for FGFR1 amplification using a dual color FISH. We found heterogeneous and different patterns of gene copy numbers. FGFR1 amplifications were observed in 20% of pulmonary squamous carcinomas but not in adenocarcinomas. High-level amplification (as defined by an FGFR1/centromer 8 (CEN8) ratio ≥2.0, or average number of FGFR1 signals per tumor cell nucleus ≥6, or the percentage of tumor cells containing ≥15 FGFR1 signals or large clusters ≥10%) was detected at a frequency of 16% and low-level amplification (as defined by ≥5 FGFR1 signals in ≥50% of tumor cells) at a frequency of 4%. We conclude that FGFR1 amplification is one of the most frequent therapeutically tractable genetic lesions in pulmonary carcinomas. Standardized reporting of FGFR1 amplification in squamous carcinomas of the lung will become increasingly important to correlate therapeutic responses with FGFR1 inhibitors in clinical studies. Thus, our reading and evaluation strategy might serve as a basis for identifying patients for ongoing and upcoming clinical trials.

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.2012.102DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4089812PMC
November 2012
66 Reads

Publication Analysis

Top Keywords

fgfr1 amplification
20
fgfr1
14
squamous carcinomas
12
fgfr1 signals
12
lung cancer
12
fgfr1 amplifications
8
amplification defined
8
squamous cell
8
therapeutically tractable
8
clinical studies
8
pulmonary carcinomas
8
in-situ hybridization
8
fluorescence in-situ
8
evaluation strategy
8
reading evaluation
8
cell lung
8
tumor cells
8
amplification
7
carcinomas
6
squamous
5

References

(Supplied by CrossRef)

TS Mok et al.
N Engl J Med 2009

M Soda et al.
Nature 2007

EL Kwak et al.
N Engl J Med 2010

AT Shaw et al.
Lancet Oncol 2011

SA Khuder et al.
Lung Cancer 2001

J Weiss et al.
Sci Transl Med 2010

VP Eswarakumar et al.
Cytokine Growth Factor Rev 2005

R Grose et al.
Cytokine Growth Factor Rev 2005

M Mohammadi et al.
Cytokine Growth Factor Rev 2005

M Koziczak et al.
Oncogene 2004

U Cavallaro et al.
Nature Rev Cancer 2004

Similar Publications